



*of Ophthalmology*

- **Duke University School of Medicine**, Duke University Eye Center 2001 – 2005
  - *Assistant Professor of Ophthalmology*
  - *Director*, Medical Retina Service and Medical Retina Fellowship Program
    - Manage administrative issues related to the medical retina service
    - Manage and supervise weekly fluorescein angiography conference
  - *Director*, The Duke Center for Macular Degeneration
    - Lead multi-disciplinary macular degeneration center steering committee
    - Develop and manage a comprehensive macular degeneration patient care and education program
- **The Wilmer Ophthalmological Institute**, The Johns Hopkins Hospital, 2000 – 2001  
*Assistant Professor of Ophthalmology*

**Entrepreneurial Accomplishments**

- InnoRx, Inc.
  - Ocular drug delivery and development company
  - Acquired by SurModics in 2005

**Sponsored Clinical Research**

- Genentech, *Primary Investigator: Sailor Trial*
- MacTel Study, NEI, *Primary Investigator*
- Allergan, *Primary Investigator: Posurdex Trial*
- Acuity Pharmaceuticals
- AREDS II, *Primary Investigator*
- Alcon Pharmaceuticals, *Primary Investigator: Anecortave Acetate vs. Placebo in Prophylaxis of CNV* 2003 – 2005
- EyeTech Pharmaceuticals/Pfizer, *Primary Investigator: Diabetic Macular Edema and AMD Trials* 2002 – 2005
- Genentech Pharmaceuticals, *Co-Investigator: Photodynamic Therapy* 2002 – 2005

*with Visudyne vs. rhu-FAB*

- VisionCare Ophthalmic Technologies, *Co-Investigator: Implantable Miniature Telescope Trial* 2002 – 2005
- Diabetic Macular Edema Clinical Research Network, The National Eye Institute, *Primary Investigator: Modified Grid Laser for Diabetic Macular Edema Trial* 2002 – 2005
- Notal Vision, *Primary Investigator: MCPT Trial* 2001 – 2002
  - Established relationship with The Wilmer Eye Institute Fundus Photograph Reading Center
- Treatment of Geographic Atrophy with Zeaxanthin Trial, *Primary Investigator* 2001 – 2002
  - Served as primary investigator and supervised clinical trial coordinator
  - Clinical trial protocol development and implementation
  - Provided ophthalmology ad clinical trial in-services to cross-functional teams at the WCTB

**Data Safety and Monitoring Boards**

- Macular Translocation Surgery Trial 2002 – 2005

**Advisory Boards**

- Genentech Lucentis Team 2005 – Present
- Johnson & Johnson Ophthalmic Advisory Board 2004 – Present
- Alcon Retaane Americas Advisory Board 2004 – Present
- Novartis Visudyne Speakers Bureau 2003 – Present
- AAO SIT Retina Board 2003 – Present
- Bausch & Lomb International Nutritional Advisory Board 2003 – Present
- Bausch & Lomb International Vitreoretinal Surgery Advisory Board 2002 – Present
- The National Association of the Visually Handicapped 2002 – Present

### AAO Activities

- Retina SIT Forum 2003 – 2004

### Ad Hoc Editor

- *Retinopathy Reporter*, Editor-in-Chief 2006 – Present
- *Ophthalmology* 2001 – Present
- *Retina* 2001 – Present
- *American Journal of Ophthalmology* 2001 – Present

### Certifications and Licenses

- Board Certified, American Board of Ophthalmology 2000 – Present
- Diplomat, National Board of Medical Examiners 1995 – Present
- Licensed Physician, State of Virginia 2002 – Present
- Licensed Physician, State of North Carolina 2001 – Present
- Licensed Physician, State of Maryland 1998 – Present
- Licensed Physician, State of New York 1994 – Present

### Professional Memberships

- The Retina Society 2006 – Present
- The New York State Ophthalmological Society 2004 – Present
- The American Society of Retina Specialists 2001 – Present
- The Association for Research in Vision and Ophthalmology 1995 – Present
- The American Academy of Ophthalmology 1995 – Present
- The North Carolina Ophthalmological Society 2002 – 2005

### Consulting Relationships

- Bausch & Lomb 2000 – Present
  - Consultant in ophthalmology and vitreoretinal disease, clinical trial development, strategy, marketing, and product launch

- Genentech 2005 – Present
- Schering-Plough Pharmaceuticals 2002 – 2003
  - Consultant in vitreoretinal disease, clinical trial development, and retinal toxicology
- Medical Action Communications 2002 – 2004
  - Consultant in macular degeneration and vitreoretinal disease, retinal practice management, physician education, and publication planning
- Quintiles 2002 – 2003
  - Consultant in vitreoretinal disease and market analysis
  - Provided formal presentations and in-services to cross-functional teams

### Current Research Projects

Fackler T, Bearely S, Fekrat S, Cooney MJ. Intravitreal triamcinolone as an adjunctive therapy in photodynamic therapy with verteporfin.

Ahmad S, Bearely, Cooney MJ, Fekrat S. Photodynamic therapy with verteporfin for large subretinal hemorrhage secondary to AMD.

### Invited Lectures

*“Siena College: Impact on personal and professional development”*. Siena College Presidential Scholarship Forum, February 2003.

### Media Events

“NBC Your Total Health: Nutritionals for Macular Degeneration”, January 2007.

“Bausch & Lomb Macular Degeneration Infomercial”. *PBS/American Medical Review*, January 2003.

“Macular Degeneration: Questions and Answers”. *CBS/WRAL*, January 2003.

“Macular Degeneration and Sunlight: Role of Eye Protection”. *CBS/WRAL*, September 2002.

“Macular Degeneration: Question & Answer”. *The New York Times Magazine*, June 16 and September 15, 2002.

“Macular Degeneration”. *National Radio Medical Minute*, June 2002.

“Macular Degeneration”. *The People’s Pharmacy, National Public Radio*, June 2002.

“A Clear Vision”. *Duke Med Magazine*, Spring/Summer 2002.

“The Duke Center for Macular Degeneration: Creating an Integrated Approach to AMD Patient Care”. *M.D. News Magazine*, January 2002.

## Publications, Book Chapters, Abstracts, and Presentations

Myung JS, Bhatnagar P, Spaide RF, Klancnik JM, Cooney MJ, Yannuzzi LA, Freund KB. Long-term outcomes of intravitreal anti-vascular endothelial growth factor therapy for the management of choroidal neovascularization in pseudoxanthoma elasticum. *Retina*. 2010 May; 30(5):748-55.

Lima LH, Zweifel SA, Engelbert M, Sorenson JA, Slakter JS, Cooney MJ, Klancnik JM, Yannuzzi LA, Freund KB. Evaluation of safety for bilateral same-day intravitreal injections of anti-vascular endothelial growth factor therapy. *Retina*. 2009 Oct; 29(9):1213-7.

Levine JP, Marcus I, Sorenson JA, Spaide RF, Cooney MJ, Freund KB. Macular hemorrhage in neovascular age-related macular degeneration after stabilization with antiangiogenic therapy. *Retina*. 2009 Sep; 29(8):1074-9.

Pearlman RB, Golchet PR, Feldmann MG, Yannuzzi LA, Cooney MJ, Thorne JE, Folk JC, Ryan EH, Agarwal A, Barnes KC, Becker KG, Jampol LM. Increased prevalence of autoimmunity in patients with white spot syndromes and their family members. *Arch Ophthalmol*. 2009 July; 127(7):869-74.

Diabetic Retinopathy Clinical Research Network, Brucker AJ, Qin H, Antoszyk AN, Beck RW, Bressler NM, Browning DJ, Elman MJ, Glassman AR, Gross JG, Kollman C, Wells JA 3<sup>rd</sup>. Observational study of the development of the diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings. *Arch Ophthalmol*. 2009 Feb; 127(2):132-40.

Browning DJ, Glassman AR, Aiello LP, Bressler NM, Bressler SB, Danis RP, Davis MD, Ferris FL, Huang SS, Kaiser PK, Kollman C, Sadda S, Scott IU, Qin J, Diabetic Retinopathy Clinical Research Network. Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema. *Ophthalmology*. 2008 Aug; 115(8): 1366-71, 1371.e1.

Clemons TE, Gillies MC, Chew EY, Bird AC, Peto T, Figueroa M, Harrington MW, Macular Telangiectasia Research Group. The National Eye Institute Visual Function Questionnaire in the Macular Telangiectasia (MacTel) Project. *Invest Ophthalmol Vis Sci*. 2008 Oct; 49(10):4340-6. Epub 2008 Jun 27.

Ahmad S, Bearelyly S, Stinnett SS, Cooney MJ, Fekrat S. Photodynamic therapy for predominantly hemorrhagic lesions in neovascular age-related macular degeneration. *AM J Ophthalmol*. 2008 Jun; 145(6):1052-1057. Epub 2008 Apr 9.

Koizumi H, Cooney MJ, Leys A, Spaide RF. Centripetal retinal capillary proliferation in idiopathic parafoveal telangiectasis. *Br J Ophthalmol*. 2007 Dec; 91(12):1719-20.

Bhatnager P, Freund KB, Spaide RF, Klancnik JM Jr, Cooney MJ, Ho I, Fine HF, Yannuzzi LA. Intravitreal bevacizumab for the management of choroidal neovascularization in pseudoxanthoma elasticum. *Retina*. 2007 Sep; 27(7):897-902.

Bhatnager P, Spaide RF, Takahashi BS, Peragallo JH, Freund KB, Klancnik JM Jr, Cooney MJ, Sorenson JA, Yannuzzi LA. Ranibizumab for treatment of choroidal neovascularization secondary to age-related macular degeneration. *Retina*. 2007 Sep; 27(7):846-50.

Bearely S, Cooney MJ, Stinnett SS, Fekrat S. Intravitreal triamcinolone for cystoid macular edema related to branch retinal vein occlusion. *Ann Ophthalmol (Skokie)*. 2006 Winter; 38(4): 317-20.

Meyerle CB, Freund KB, Iturralde D, Spaide RF, Sorenson JA, Slakter JS, Klancnik JM Jr, Fisher YL, Cooney MJ, Yannuzzi LA. Intravitreal bevacizumab (Avastin) for retinal angiomatous proliferation. *Retina*. 2007 Apr-May; 27(4): 451-7.

Matsumoto Y, Freund KB, Peiretti E, Cooney MJ, Ferrara DC, Yannuzzi LA. Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusion disease. *Retina*. 2007 Apr-May; 27(4):426-31.

Fackler TK, Reddy S, Bearely S, Stinnett S, Fekrat S, Cooney, MJ. Retrospective review of eyes with neovascular age related macular degeneration treated with photodynamic therapy in verteporfin and intravitreal triamcinolone. *Ann Acad Med Singapore*. 2006 Oct; 35(19): 701-5.

Spaide RF, Laud K, Fine HF, Klancnik JM Jr, Meyerle CB, Yannuzzi LA, Sorenson JA, Slakter JS, Fisher YL, Cooney MJ. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. *Retina*. 2006 Apr; 26(4): 383-90.

Reeves SW, Miele DL, Woodward JA, Cummings TJ, Eales MC, Kurz P, Cooney MJ. Retinal folds as initial manifestation of orbital lymphangioma. *Arch Ophthalmol*. 2005 Dec; 123(12): 1756-8.

Goldstein M, Loewenstein A, Barak A, Pollack A, Bukelman A, Katz H, Springer A, Schachat AP, Bressler NM, Bressler SB, Cooney MJ, Alster Y, Rafaeli O, Malach R, Preferential Hyperacuity Perimeter Research Group. *Retina*. 2005 Apr-May; 25(3):296-303.

Joy SV, Scates AC, Bearely S, Dar M, Taulien CA, Goebel JA, Cooney MJ. Ruboxistaurin, a protein kinase C beta inhibitor as an emerging treatment for diabetic microvascular complications. *The Annals of Pharmacotherapy* 2005, Oct; 39(10):1693-9.

Fackler T, Bearely S, Stinnet S, Fekrat S, Cooney MJ. Retrospective review of eyes with neovascular age-related macular degeneration treated with combined photodynamic therapy with verteporfin and intravitreal triamcinolone. *Accepted Singapore Journal of Ophthalmology 2005*.

Bearely S, Stinnet S, Fekrat S, Cooney MJ. Intravitreal Triamcinolone in eyes with cystoid macular edema secondary to branch vein occlusion. *Accepted Singapore Journal of Ophthalmology 2005*.

Goldstein M, Loewenstein A, Barak A, Pollack A, Bukelman A, Katz H, Springer A, Schachat AP, Bressler NM, Bressler SB, Cooney MJ, Alster Y, Rafaeli O, Malach R, PHP Research Group. Results of a multicenter clinical trial to evaluate the preferential hyperacuity perimeter for detection of age-related macular degeneration. *Retina*. 2005 Apr-May,25(3):296-303.

Cooney MJ. Current and evolving therapies for neovascular AMD 2005. *Retinal Physician*, November 2005.

Cooney MJ. Ocular Drug Delivery. *Retinal Physician*, Spring 2005.

Reeves S, Miele D, Woodward J, Cummings TJ, Eales M, Kurz P, Cooney MJ. Orbital lymphangioma presenting with retinal folds. Accepted *Archives of Ophthalmology* 2004.

Sunness JS, Cooney MJ, Neuwirth J, Stone EM. Diagnostic and therapeutic challenges. *Retina* 2004, Dec;24(6):957-61.

Kurz P, Cooney MJ. Patient-centered macular degeneration care. *The Retina Times*. 2004.

Kurz P, Nguyen H., Cooney MJ. Bilateral Foveal Neovascularization in Proliferative Diabetic Retinopathy. *Archives of Ophthalmology* 2003 Nov; 121(11):1656-7.

Chen JJ, Winarko TK, Cooney MJ. Age-related macular degeneration: An overview for the pharmacist. *Pharmacy Times* May 2003.

Nakajima M, Cooney MJ, Tu A, Chang KY, de Juan E. Genistein reduces retinal vascular permeability in the streptozotocin diabetic rat. *Investigative Ophthalmology & Visual Science* 2001; 42:2110-2114.

Cooney MJ, Pieramici DJ. Choroidal-retinal arteriole anastomosis after penetrating ocular trauma. *Retina* 2000; 20:552-554.

Cooney MJ. Photocoagulation in AMD: Does laser wavelength matter? *Ophthalmology Management* 2000;4:60-66.

Lai J, Cooney MJ. History of Photodynamic Therapy. *International Ophthalmology Clinics*, 1999; 39:163-174.

DeJuan E, Cooney MJ, Humuyan MS, Jensen PS. Treatment of retinal disease in the new millennium. *Ophthalmology Clinics of North America* 1999; 12:539-562.

Speer C, Pearlman J, Phillips PH, Cooney MJ, Repka MX. Fourth cranial nerve palsy in pediatric patients with pseudotumor cerebri. *American Journal of Ophthalmology* 1999; 127(2): 236-237.

Cooney MJ, Bressler NM. Retinal hemorrhage in a patient with AMD and diabetic retinopathy. *The Wilmer Retina Update* 1999;5:32-34.

Cooney MJ, Bressler NM. Laser for juxtafoveal choroidal neovascularization in age-related macular degeneration: *Better than no treatment*. *The Wilmer Retina Update* 1999;5:1-3.



Cooney MJ, Bressler NM. Branch retinal vein occlusion masquerading as occult choroidal neovascularization. *The Wilmer Retina Update*, 1999.

Cooney MJ, Bressler NM. Successful treatment of recurrent juxtafoveal choroidal neovascularization secondary to POHS. *The Wilmer Retina Update* 1999;5:40-43.

Cooney MJ, Bressler NM. Retinal telangiectasis with optic nerve leakage. *The Wilmer Retina Update* 1999;5:44-47.

Cooney MJ. Eye injuries caused by bungee cords. Letter. *Ophthalmology* 1998; 105:941.

Cooney MJ, Schachat AP. Screening for diabetic retinopathy. *International Ophthalmology Clinics* 1998; 38:111-122.

Cooney MJ, Fekrat S, Finkelstein D. Natural history and clinical management of central retinal vein occlusion. *Current Opinion in Ophthalmology* 1998; 9:47-50.

Cooney MJ. Metallothionein: A prognostic factor in uveal melanoma. *Ophthalmology Times* 1998;3:47.

Cooney MJ, Bressler NM. Occult choroidal neovascularization adjacent to a juxtafoveal serous detachment of the retinal pigment epithelium: What is the best management? *The Wilmer Retina Update* 1998;4:87-90.

Cooney MJ, Pieramici DJ. Eye injuries caused by bungee cords. *Ophthalmology* 1997; 104:1644-1647.

Pieramici DJ, Cooney MJ, Bressler SB. Treatment of long-standing diabetic premacular hemorrhage with Nd:Yag membranotomy. *The Wilmer Retina Update* 1997;3:27-31.

Cooney MJ. Persistent bleb leak after glaucoma filtration surgery. *Ophthalmology Times* 1997;22:20-21.

Cooney MJ, Friella PJ, Azar DT. Eye infections after refractive surgical procedures. *Ophthalmic Practice* 1996; 14:43-47.

Leib ML, Odel JG, Cooney MJ. Orbital polymyositis and giant cell myocarditis. *Ophthalmology* 1994; 104:950-955.

Bhatia SK, Cooney MJ, Shriver-Lake L, Fare TL, Ligler FS. Immobilization of acetylcholinesterase on solid surfaces: Chemistry and Activity Studies. *Sensors and Activators B*, 3 (1991) 311-317.

## Book Chapters and Book Reviews

Bearnelly S and Cooney MJ. Age-Related Macular Degeneration: Duke University's All About Your Eyes. In Press.

Park C, Oh M, Cooney MJ, Fekrat S. Fluorescein Angiographic Findings in Retinal Vascular Diseases. 2<sup>nd</sup> Edition. Cultura Medica.

Ladd BS and Cooney MJ. Thickened or Elevated Macular Retina. Clinical Pathways in Vitreoretinal Disease. Thieme; 2003, 245 – 262.

Solomon S, Cooney MJ, Sunness J. "Geographic Atrophy". In: Lim J, ed. *Age Related Macular Degeneration*. New York: Marcel Dekker, Inc. 2000.

Cooney MJ, Fekrat S. Retinal Artery Macroaneurysms. In: Quiroz-Mercado H, Liggett P, Alfaro V, de Juan E, Tano Y, eds. *Macular Surgery*. Philadelphia: Lippincott-Raven; 2000; 154-157.

Cooney MJ. Review of "Ophthalmic Ultrasound: A Diagnostic Atlas", 1<sup>st</sup> edition, DiBernardo, Schachat, and Fekrat. Doody Publishing Review, 1999.

Cooney MJ, Quigley HA. Glaucomatous Emergencies. In: MacCumber MW, ed. *The Management of Ocular Injuries and Emergencies*. Philadelphia: Lippincott-Raven; 1998; 235-256.

Cooney MJ, Schachat AP. Combined Hamartoma of the Retina and Retinal Pigment Epithelium. In: Chang S, Yannuzzi L, Green WR, eds. *Retina-Vitreous-Macula: A Comprehensive Text*. Philadelphia: W.B. Saunders; 1998; 1123-1129.

Cooney MJ. Review of "Manual of Ocular Diagnosis and Therapy", 4<sup>th</sup> edition, Deborah Pavan-Langston. *American Journal of Ophthalmology*, 1997.

## Abstracts and Posters

Bearnelly S, Ahmad S, Stinnet S, Cooney M, Fekrat S. Photodynamic therapy with verteporfin for predominantly hemorrhagic choroidal neovascular lesions in neovascular age-related macular degeneration. IOVS 2005, 332/B306.

Fackler T, Bearnelly S, Stinnet S, Fekrat S, Cooney MJ. Retrospective review of eyes with neovascular age-related macular degeneration treated with combined photodynamic therapy with verteporfin and intravitreal triamcinolone. IOVS 2005 46: E-abstract 332.

Bearnelly S, Fekrat S, Cooney MJ. Intravitreal triamcinolone in eyes with cystoid macular edema secondary to branch retinal vein occlusion. IOVS 2004 45: E-abstract 5235.

Mahmoud ME, Cooney M, de Juan E. Pharmacokinetics of genistein distribution in blood and retinas of diabetic and non-diabetic rats. IOVS 2003 44: E-abstract 3594.

Kurz P, Ward M, Cooney M. Assessment of effectiveness of communication of information and available resources to patients with age-related macular degeneration. IOVS 2003 44: E-abstract 1823.

Mahmoud ME, Cooney M, de Juan E. Multi-dose efficacy study of genistein in laser-induced choroidal neovascularization in primates. IOVS 2002 43: E-abstract 1283.

De Juan E, Mahmoud M, Cao J, Cooney M, Majit A, Jensen R. Effect of genistein on angiogenic growth factors in the zucker diabetic fatty rat. ARVO 2001.

Fujii G, De Juan E, Sunness J, Melia M, Humayun MS, Pieramici D, Cooney M. Patient selection for macular translocation surgery using scanning laser ophthalmoscope. ARVO 2001.

## Presentations

“Medical management of diabetic retinopathy 2005”. Schupf Symposium, 2005.

“The Role of nutrition in macular degeneration”. JJ Bausch Lecture Series AAO 2005.

“Referral Patterns for Uveitis”. B&L RetiSert Training Meeting, 2005.

“Anecortave Acetate for Macular Degeneration”. ASCRS Alcon Booth Lecture Series, 2005.

“Nutritionals for Macular Degeneration”. World Ophthalmology Congress, Brazil, 2005.

“Diffuse Peripapillary Melanoma”. Atlantic Coast Fluorescein Conference 2005.

“Drug delivery methods for macular degeneration”. Emerging AMD Therapies Symposium AAO 2004.

“The Role of nutrition in macular degeneration”. JJ Bausch Lecture Series AAO 2004.

“AMD and The Duke Center for Macular Degeneration”. Duke Medical Alumni Grand Rounds 2004.

“The Role of nutrition in macular degeneration”. Grand Rounds St. Vincents Hospital, Department of Ophthalmology, September 2004.

“The Role of nutrition in macular degeneration”. Canadian Ophthalmological Society Meeting 2004.

“Simultaneous bilateral neurosensory detachments as the presenting sign of ALL”. ASRS Fluorescein Conference 2004.

“Exploring the current and investigational AMD therapies”. Alcon Retaane Advisory Board Meeting 2004.

“Macular Degeneration 2004”. Duke Palm Beach Forum 2004.

“AMD and The Duke Center for Macular Degeneration”. Beard Center for Aging, Lynchburg College 2004.

“Macular Degeneration 2004”. North Carolina Society of Eye Physicians Meeting 2004.

“The NEI Diabetic Clinical Research Network”. Duke AVS Course 2004.

“The Anecortave Acetate Risk Reduction Trial (AART)”. Duke AVS Course 2004.

“The Role of nutrition in macular degeneration”. ISOPT 2004.

“Macular Degeneration: What the internist needs to know”. Duke Internal Medicine Grand Rounds, December 2003.

“Photodynamic Therapy for Subfoveal CNV in Parafoveal Telangiectasis”. The American Society of Retinal Specialists, August 2003.

“Nutrition and macular degeneration”. JJ Bausch Lecture Series, AAO 2003.

Macular Degeneration Staff Training In-Service. Duke Eye Center, June 2003.

“Management of CNV 2003”. Duke Vision Symposium, May 2003.

“AMD Update 2003”. Duke Vision Symposium, May 2003.

“Use of OCT in PDT and Peripheral Retinal Pathology”. Duke OCT Course, May 2003.

“The ABC’s of Macular Degeneration.” The Duke Macular Degeneration Center Quarterly Patient Lecture Series. April 2003.

“Macular Degeneration: What you need to know”. Carolina Meadows Retirement Center, March 2003.

“The opportunities and challenges of organizational integration at the Duke Eye Center”. Duke Eye Center Faculty Retreat, February 2003.

“Age Related Macular Degeneration”. Duke Medical Student Lecture Series. February 2003.

“Macular Degeneration: What you need to know”. Troy AARP Chapter Meeting, November 2002.

“Macular Degeneration: What you need to know”. Raleigh 55-Plus Club Chapter Meeting, November

2002.

“Macular Degeneration and the Macular Degeneration Patient”. Bausch & Lomb Symposium, AAO 2002.

“Diabetes and Uveitis Patient Referral Streams”. Bausch & Lomb Symposium, The Retina Congress 2002.

“Neovascular Age-Related Macular Degeneration”. Duke Residents Lecture Series, Fall 2002.

“Non-neovascular Age-Related Macular Degeneration”. Duke Residents Lecture Series, Fall 2002.

“Fascioscapulohumeral dystrophy and retinal telangiectasis”. The Retina Congress Fluorescein Conference 2002.

“The Duke Center for Macular Degeneration: What, When, How, Where, and Why”. The Optometric Continuing Education Symposium 2002.

“The Duke Center for Macular Degeneration”. Duke Chairman’s Science of Disease Lecture, July 2002.

“Macular Degeneration: What you need to know” and “The Duke Center for Macular Degeneration: What, When, How, Where, and Why”. Coping With Macular Degeneration Conference Summer 2002.

“Age-Related Macular Degeneration, Diabetic Retinopathy and Refractive Surgery: A Review for Internists”. American College of Physicians Annual Meeting, April 2002.

“The Duke Center for Macular Degeneration”. The Duke Eye Center Advisory Board Meeting, Spring 2002.

“The Role of laser in the photodynamic therapy era”. Duke Advanced Vitreoretinal Surgical Course 2002.

“Current Management of Diabetic Macular Edema”. Duke Advanced Vitreoretinal Surgical Course 2002.

“Genistein ameliorates retinal vascular leakage in the streptozocin diabetic rat”. Duke Advanced Vitreoretinal Surgical Course 2002.

“Macular Degeneration: What you need to know”. Teer House Community Lecture Series, March 2002.

“The Duke Center for Macular Degeneration”. Duke Clinical Support Staff In-Service, January 2002.

“Macular Degeneration: What you need to know”. Marriott Brighton Gardens Community Lecture Series, January 2002.

“Fascioscapulohumeral dystrophy and retinal telangiectasis”. The Atlantic Coast Fluorescein Conference 2002.

“Neovascular Age-Related Macular Degeneration”. Duke Residents Lecture Series, Winter 2002.

“Non-neovascular Age-Related Macular Degeneration”. Duke Residents Lecture Series, Fall 2001.

“The geographic atrophy/zeaxanthin (GAZ) clinical trial.” The Wilmer Residents Association Meeting. April, 2001.

“The Clinical Development of Pharmaceuticals.” The Wilmer Study Coordinator Network. April, 2001.

“Genistein ameliorates retinal vascular leakage in the streptozocin diabetic rat.” The 12<sup>th</sup> Annual Wilmer Research Meeting. March, 2001.

“New developments in vitreoretinal surgical instrumentation: twenty-five gauge instrumentation.” The Wilmer Current Concepts in Ophthalmology Meeting. December, 2000.

“The geographic atrophy/zeaxanthin (GAZ) clinical trial.” The Wilmer Current Concepts in Ophthalmology Meeting. December, 2000.

“Genistein ameliorates retinal vascular leakage in the streptozocin diabetic rat.” Mid-Atlantic Diabetes Research Symposium, National Institutes of Health. October, 2000.

“Overview of ophthalmology.” Wilmer Clinical Trials and Biometry Research Center. August, 2000.

“Drug delivery requirements from a surgeon/patient perspective.” Bausch & Lomb Opinion Forum in Ocular Drug Delivery. May, 1999.

“Bis-hydroxy-2-ethyl-terephthalate in ocular drug delivery.” The Wilmer Residents Meeting. May, 1999.

“Macular Translocation: Clinical requirements and techniques.” The Wilmer Pavilion In-service. February, 1999.

“Clinical management of branch retinal vein occlusion.” The Wilmer Retinal Vascular Center Diabetes and Vein Occlusion Conference. October, 1998.

“Use of an intraocular gas bubble in vitreoretinal surgery: What does the nursing staff need to know?” The Wilmer Pavilion In-service. September, 1998.

“Pediatric Eye Trauma, Emergency eye care in the field: A program for pre-hospital care providers.” The Wilmer Institute. June, 1998.

“Biocompatible polymers for ocular drug/protein/gene delivery.” The Wilmer Residents Meeting. May, 1998.

“Topical mitomycin C in the treatment of ocular surface neoplasia.” The Wilmer Residents Clinical Challenges Conference. January, 1998.

“Eye injuries caused by bungee cords.” The Wilmer Residents Meeting and The Association for Research in Vision and Ophthalmology. May, 1997.

“Nd:YAG laser membranotomy in the treatment of premacular hemorrhages.” The Wilmer Residents Clinical Challenges Conference and The Age-Related Macular Degeneration Update. February and May, 1997.

“Eye infections after refractive surgical procedures.” The Wilmer Residents Meeting. May, 1996.

“Glaucoma emergencies.” Management of Ocular Emergencies Conference. The Wilmer Institute. February, 1996.

“VISION”. The National Eye Institute School Education Program. The Cathedral of Mary Our Queen, Baltimore, MD. Fall, 1995.